DOI: 10.1515/cipms-2018-0009

Curr. Issues Pharm. Med. Sci., Vol. 31, No. 1, Pages 39-43

DE GRUYTER OPEN

Current Issues in Pharmacy and Medical Sciences

Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA

journal homepage: http://www.curipms.umlub.pl/

Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin in bulk and tablet dosage form

Thiyagarajan Deepan[1,2], Magharla Dasaratha Dhanaraju[2]*

[1] Research Scholar, Krishna University, Andhra Pradesh, India

[2] Research Lab., GIET School of Pharmacy, Chaitanya Knowledge City, Rajahmundry, 533294 Andhra Pradesh, India

ARTICLE INFO

Received 09 October 2017
Accepted 08 January 2018

Keywords:
Dapagliflozin,
Saxagliptin,
HPLC,
degradation studies,
stability indicating.

ABSTRACT

A simple, fast, and highly selective RP-HPLC method was developed for the determination of Dapagliflozin (DAP) and Saxagliptin (SAX) in API and tablet dosage form. The separation was done using a Xterra RP18 (4.6×150 mm, 5 μm particle size) column with Acetonitrile: water (60:40). The isocratic elution mode at a flow rate of 1 mL/min, and the analytes were measured at 248 nm. The retention time for DAP and SAX were about 2.091 and 3.249 min, respectively. Calibration curves were found to be linear in the ranges of 100-500 μg/ml for DAP and 50-250 μg/ml for SAX, with correlation coefficients of 0.9998. The detection and quantification values for DAP was 3.0 and 9.98 μg/ml and SAX was 3.02 and 10 μg/ml respectively.

INTRODUCTION

Dapagliflozin is chemically known as (1S)-1, 5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl] phenyl]-D-glucitol (Fig. 1a). Saxagliptin is chemically known as (1S,3S,5S)-2-{(2S)-2Amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl}-2-azabicyclo[3.1.0] hexane-3 carbonitrile [1,2] (Fig. 1b). A Literature survey shows that numerous analytical methods are reported for the individual estimation of DAP and SAX or with other pharmaceutical preparations, by various methods such as UV spectrophotometry [3] HPLC [4-8], HPTLC [10,11], UPLC [12], LC MS [13-15]. On the other hand, there is no method reported for dapagliflozin and saxagliptin by HPLC. Hence there is a need for a sensitive HPLC method which is stable and indicating for DAP and SAX. Stability studies was carried out by forcing the drug under variety of stress conditions such as thermal, oxidative, light and hydrolysis (acid and base), The established HPLC method was validated as per ICH guidelines [16].

MATERIALS AND METHODS

Chemicals

DAP and SAX were obtained as a gift from Glenmark Pharma&Piramal healthcare (India). Fixed dose combination of tablet formulation Qtern tablets (AstraZeneca) containing 10 mg/5 mg of DAP and SAX were procured form local market. HPLC grade acetonitrile and water were procured from Merck, India. A membrane filter of 0.45 μm porosity was used to filter and degassed the mobile phase. Chemicals used were of analytical or HPLC grade.

Instrumentation and materials

Waters HPLC 2695 was used for analysis. The separation was done on a UV detector and sampling was done by auto sampler. Data collection for chromatogram was done by empower software 2. The column used was Xterra column (150×4.6 mm) with mobile phase composition of

Figure 1a. Structure of Dapagliflozin

Figure 1b. Structure of Saxagliptin

* **Corresponding author**
e-mail: mddhanaraju@yahoo.com; mddhanaraju@gmail.com

© 2018 Medical University of Lublin. This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)

acetonitrile: water (60:40). Filtration of mobile phase was carried out by 0.45 μm membrane filter under the isocratic condition with flow rate of 1.0 ml/min, injected volume was 20 μL and elution monitored at 248 nm with run time of 10 min.

PREPARATION OF SOLUTION

Standard preparation

Standard stock solutions were set by dissolving 10 mg of DAP and 5 mg of SAX in acetonitrile: water (60:40) mixture as diluents in 10 ml volumetric flask to achieve concentration of 1000 μg/ml for Dap and 500 μg/ml for SAX respectively. It was sonicated followed by filtration using 0.45 μm porosity filter paper. The stock solution was diluted by pipetted out 3 ml of above solution into 10 ml volumetric flask to produce reference standard solution containing DAP (300 μg/ml) and (SAX 150 μg/ml), respectively.

Sample preparation

Weight equivalent to powder containing 10 mg of DAP and 5 mg of SAX were dissolved in a 10 ml clean dry volumetric flask and diluent was added. It was sonicated, followed by filtration using 0.45 μm porosity filter paper (stock solution). We further pipetted 3 ml of Dapagliflozin and Saxagliptin from the above stock solution into a 10 ml volumetric flask and diluted up to the mark with diluent. The solutions were subject to analysis and results shown in Table 5.

DEGRADATION STUDIES

Preparation of stock

The stock solution was prepared by dissolving 10 mg of DAP and 5 mg of SAX in acetonitrile: water (60:40) mixture as diluents in 10 ml volumetric flask and then sonicated for 10 min and finally made up to the volume (Stock solution).

Hydrolytic degradation under acidic condition

The acid hydrolysis was done by pipetted out 3 ml of solution along with 3 ml of 0.1 N HCl into 10 ml volumetric flask. This was kept at 60°C for 24 hours and then neutralized with 0.1 N NaOH, followed by filtration with 0.45 μm syringe filter and placement in vials.

Hydrolytic degradation under alkaline condition

The base hydrolysis was carried out by pipetted out 3 ml of solution along with 3 ml of 0.1 N NaOH into 10 ml volumetric flask. This was kept at 60°C for 24 hours and then neutralized with 0.1 N Hcl, followed by filtration with 0.45 μm syringe filter and placed in vials.

Thermal induced degradation

Thermal degradation was carried out by placing solid samples and tablets in a Petridish and keeping these in a hot air oven at 110°C for 3 hrs, followed by filtration with 0.45 μm syringe filter and placed in vials.

Oxidative degradation

The oxidative degradation was carried out by pipetted out 3 ml of solution along with 1 ml of 12.5% w/v of hydrogen peroxide into a 10 ml volumetric flask. This was then kept at room temperature for 15 min, followed by filtration with 0.45 μm syringe filter and placed in vials.

Photo degradation

The photolytic degradation was carried out by taking solid samples and tablets placing these spread out as a thin layer on a Petri plates. It subsequently exposed to UV light in a chamber for 48 hrs. The stressed sample was filtered through 0.45 μm syringe filter before its analysis.

Validation parameters[16]

Accuracy

The accuracy method was performed by utilizing the standard additional method. The concentration of drug at different levels (50%, 100%, 150%) was evaluated and the mean recovery of DAP and SAX was calculated.

Precision

Intraday precision was performed by taking a concentration of 300 μg/mL for Dapagliflozin and 150 μg/mL for Saxagliptin on the same day. The inter day precision were carried out at a similar concentration on three days by different operators, respectively. The standard solution was injected for six times and the area for all six Injections was measured in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Linearity

The linearity was done by diluting the stock solution with mobile phase to yield a concentration of 100-500 μg/mL for DAP and 50-250 μg/mL for SAX. The linearity was performed by linear regression analysis using least square method.

Robustness

Robustness was done by varying slight changes in the parameters such as the mobile phase composition, flow rate, wavelength and column temperature.

System suitability study

System suitability tests were carried out on a freshly prepared standard solution of the DAP and SAX to analyse the various optimized parameters such as (eg. Theoretical plates, resolution and tailing factor).

RESULTS AND DISCUSSION

The chromatographic method was optimized by varying parameters, such as flow rate, mobile phase, column temperature and detection wavelength. The method was performed with various columns such as the C18 column, Hypersil column, Lichrosorb and Intersil ODS column. Xterra RP18 (4.6×150 mm, 5 mm) were found to be ideal as it gives

good peak shape and resolution at 1.0 ml per min flow. The method was optimized with mobile phase composition of acetonitrile and water 60:40 (v/v) at a flow rate of 1 mL/min and at 248 nm by using a Xterra RP18 (4.6×150 mm, 5 mm) column. The peak was eluted at less than 5 min. The results are seen in Table 1.

Table 1. Chromatographic conditions

Column	Xterra RP18 (4.6×150 mm, 5 µm particle size)
Elution method	Isocratic
Mobile phase	Acetonitrile: water (60:40)
Flow rate	1 ml/min
Column temperature	25c
Volume of injection	20 µL
Detector	UV detector
Detection wavelength	248
Run time	10 min

The retention times obtained for dapagliflozin and saxagliptin were 2.089 and 3.253 min, respectively. The standard and sample chromatogram were shown in Fig. 2 and 3, respectively. Quantitative linearity of drugs was obeyed in the concentration range of 100-500 µg/ml for DAP and 50-250 µg/ml for SAX, respectively. The relevant regression equations were y=2189.9x+32315 for dapagliflozin (r^2=0.9998) and y=2889.6x+10443 for saxagliptin (r^2=0.9998) (where y is the peak area and x is the concentration for dapagliflozin and saxagliptin. The corresponding mean recoveries for dapagliflozin and saxagliptin were 100.72% and 100.02%. This reveals that the method is quite accurate and precise. The %RSD was found to be less than 2 for accuracy and precision, indicating that the method is accurate (Table 2&2a).

Table 2. Accuracy studies (n=6)

Sample	Level (%)	Peak area	Amount recovered (µg/mL)	%RSD
Dapagliflozin	50	671842.3	100.40	0.6
	100	1361348	100.78	0.3
	150	2045898	100.97	0.1
Saxagliptin	50	432916.3	100.43	0.7
	100	861056.3	99.88	0.3
	150	1289755	99.78	0.7

Table 2a. Precision studies (n=6)

Injection	Area for Saxagliptin	Area for Dapagliflozin
Injection-1	111368	852828
Injection-2	112717	852337
Injection-3	112655	858355
Injection-4	113939	852839
Injection-5	1112.513	858513
Injection-6	112282	857582
Average	112662.3	855409.0
Standard Deviation	845.7	12.524.5
%RSD	0.8	0.4



Figure 2. Standard chromatogram of DAP and SAX



Figure 3. Sample chromatogram of DAP and SAX



Figure 4. Detection wavelength of DAP and SAX

The experimental LOD and LOQ were 3.00 µg/mL and 9.98 µg/mL for DAP, 3.02 µg/mL and 10.01 µg/mL for SAX, respectively. The validation parameters and the assay results for tablet formulation were shown in (Tables 4 and 5). System suitability parameters such as, column efficiency, resolution and tailing factor of the peaks were calculated. The tailing factor for DAP and SAX was found to be 1.40 and 1.37, respectively. Theoretical plates for DAP and SAX was 2913 and 3772. Resolution was found to be 3.96. The system suitability results are shown in (Table 6). The results of robustness studies are shown in (Table 7).

Table 3. Degradation studies

S.No	Conditions	DAP		SAX	
		R_t(min)	% degraded	R_t(min)	% degraded
1	Acid	2.075	6.7	3.235	4.3
2	Base	2.090	2.3	3.268	6.8
3	Oxidation	2.080	5.1	3.245	2.6
4	Thermal	2.081	4.9	3.219	3.4
5	UV exposure	2.074	4.3	3.240	2.5

Table 4. Summary of validation parameters

Parameter	DAP	SAX
Linearity range(µg/mL)	100-500	50-250
Regression equation	Y=2189.9x+32135	Y=2889.6x+10443
Correlation coefficient	0.9998	0.9998
LOD(µg/mL)	3.00	3.02
LOQ(µg/mL)	9.98	10.01
Interday precision(%RSD)	0.1	0.7
Intraday precision(%RSD)	0.8	0.4

Table 5. Results of assay of marketed formulation

Brand	Drug	Sample peak area	Standard peak area	Labelled amount (mg/tab)	% Assay	RSD
Qtern	DAP	1343348	1355109	10	100.27	0.7
	SAX	857190	863399	5	100.03	0.5

Table 6. System suitability results

S. No	System suitability parameters	Results	
		DAP	SAX
1	USP tailing	1.40	1.37
2	USP plate count(Rs)	2.913	3.772
3	Rt min	2.091	3.249
4	USP resolution	3.96	

Table 7. Robustness study

S.No	Parameter	Change level	DAP			SAX		
			Rt	Peak area	Tailing factor	Rt	Peak area	Tailing factor
1	Flow rate	0.9	2.318	689155	1.43	3.616	449077	1.39
		1.1	1.879	549133	1.39	2.923	360430	1.35
2	Mob. organic phase composition	50:50	2.132	568190	1.43	3.851	373590	5.70
		70:30	2.049	1653142	1.38	2.877	1076066	2.95

Forced degradation studies were carried out in acid, base, thermal, photolytic and peroxide conditions; DAP was degraded more (6.7%) in acidic conditions than in other conditions. In basic conditions, SAX was degraded more (6.8%) than other conditions (Fig. 5). For DAP and SAX, the basic conditions resulted in a significant increase in the area with the additional peaks. Under the basic conditions, a significant decrease of the peak area of DAP and SAX was observed within 5 min, with one additional peak detected at 1.459 min, respectively. This is shown in (Fig. 6). Under oxidative condition, a significant decrease of the area of DAP and SAX was detected and small degradation peaks were seen approximately at 1.458 min. This is shown in (Fig. 7). Under photo degradation, a small additional peak was detected at 6.631 min. This is seen in (Fig. 8). Under thermal condition, a slight decrease of the area was detected and one small degradation peaks were seen approximately at 1.446 min – as shown in (Fig. 9). The stressed samples were, respectively, analysed for dapagliflozin and the saxagliptin results are shown in (Table 3).



Figure 5. Chromatogram of Acid degradation (24 hrs)



Figure 6. Chromatogram of base degradation (24 hrs)



Figure 7. Chromatogram of peroxide degradation (15 min)



Figure 8. Chromatogram of photo degradation (48 hrs)



Figure 9. Chromatogram of thermal degradation (3 hrs)

CONCLUSION

The validated method shows that the stability-indicating RP-HPLC method is simple, fast and high selective, accurate and specific without any interference from the excipients and degradation products. The method was successfully applied for the quantitative analysis of DAP and SAX in marketed formulations.

ACKNOWLEDGEMENTS

The author would like to thank management, GIET School of pharmacy, Rajahmundry for providing the facilities to carry out the research work.

CONFLICTS OF INTEREST

There are no conflicts of interest.

REFERENCES

1. https://pubchem.ncbi.nlm.nih.gov/compound/Dapagliflozin
2. https://pubchem.ncbi.nlm.nih.gov/compound/Saxagliptin
3. Mante GV, Gupta KR, Hemke AT. Estimation of Dapagliflozin from its Tablet Formulation by UV-Spectrophotometry. Pharm Methods 2017;8,2:102-7.
4. Prasad PBN, Satyanarayana K, Krishnamohan G. Development and Validation ofa Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC, American Journal of Analytical Chemistry 2015;6:841-50.
5. Yunoos M, Sankar DG. A validated stability indicating high-performance liquid chromatographic method for simultaneous determination of metformin Hcl and dapagliflozin in bulk drug and tablet dosage form, Asian J Pharm Clin Res. 2015;8:320-6.
6. Cumar RP, Vasudevan M, Deecaraman A. Validated RP-HPLC Method for Simultaneous estimation of Metformin and Saxagliptin in Tablets, Rasayan. J. Chem. 2012;2:137-41.
7. Konari SN, Jacob JT. Stability indicating validated RP-HPLC technique for the Analysis of Multicomponent anti-diabetic drug combos in pharmaceutical Dosage Forms, Karbala international journal of modern medicine 2015;1(1):39-48.
8. Prakash PP, Ramesh SK, Vikas VP, Vijay BJ, Patil NP. A New RP-HPLC Method for Determination of Metformin Hcl and Saxagliptin in Tablet Dosage Form, IJPBS 2012;2:161-7.
9. Srividya S, Swetha E, Veeresham C. Development and Validation of a High Performance Thin Layer Chromatographic Method for Quantitative Analysis of Saxagliptin, American Journal of Analytical Chemistry 2015;6:797-806.
10. El-Kimary EI, Hamdy DA, Mourad SS, Barary MA. HPTLC Determination of Three Gliptins in Binary mixtures with Metformin, Journal of Chromatographic Science, 2015;54(1):78-87.
11. Gao JW, Yuan YM, Lu YS, Yao MC. Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study, Biomed. Chromatography 2012;26(12):1482-7.
12. Aubry AF, Gu H, Magnier R, Morgan L, Xu X, Tirmenstein M et al. Validated LC–MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma, Bioanalysis, 2010;2(12):2001-9,2010.
13. Batta N, Pilli NR, Derangula VR, Vurimindi HB, Damaramadugu R, Yejella RP. A Rapid and Sensitive LC-MS/MS Assay for the Determination of Saxagliptin and its Active Metabolite5-hydroxy Saxagliptin in Human Plasma and its Application to a Pharmacokinetic Study, Drug Res. 2015;65:133-40.
14. Sridhar L, Goutami P, Darshan DV, Ramakrishna K, Rao RN, Prabhakar S. LC-ESI-MS/MS studies on saxagliptin and its forced degradation Products, Anal. Methods 2014;6:8212-21.
15. Shah PA, Shah JV, Sanyal M, Shrivastav PS. LC–MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects, Biomed Chromatography, 2017;31:e3809.
16. ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use, Geneva, 2005:1-13.